Experimenting with ASL-based arterialized cerebral blood volume as a novel imaging biomarker in grading glial neoplasms.
Perfusion magnetic resonance imaging
T2*dynamic susceptibility contrast
arterial spin labeling
cerebral blood volume
glioma
Journal
The neuroradiology journal
ISSN: 2385-1996
Titre abrégé: Neuroradiol J
Pays: United States
ID NLM: 101295103
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
pmc-release:
01
12
2024
medline:
15
11
2023
pubmed:
7
8
2023
entrez:
7
8
2023
Statut:
ppublish
Résumé
Perfusion imaging is one of the methods used to grade glial neoplasms, and in this study we evaluated the role of ASL perfusion in grading brain glioma. The aim is to evaluate the role of arterialized cerebral blood volume (aCBV) of multi-delay ASL perfusion for grading glial neoplasm. This study is a prospective observational study of 56 patients with glial neoplasms of the brain who underwent surgery, and only cases with positive diagnosis of glioma are included to evaluate the novel diagnostic parameter. In the study, ASL-derived normalized aCBV (naCBV) and T2*DSC-derived normalized CBV (nCBV) are showing very high correlation (Pearson's correlation coefficient value of 0.94) in grading glial neoplasms. naCBV and nCBF are also showing very high correlation (Pearson's correlation coefficient value of 0.876). The study also provides cutoff values for differentiating LGG from HGG for normalized aCBV(naCBV) of ASL, normalized CBV (nCBV), and normalized nCBF derived from T2* DCS as 1.12, 1.254, and 1.31, respectively. ASL-derived aCBV also shows better diagnostic accuracy than ASL-derived CBF. This study is one of its kind to the best of our knowledge where multi-delay ASL perfusion-derived aCBV is used as a novel imaging biomarker for grading glial neoplasms, and it has shown high statistical correlation with T2* DSC-derived perfusion parameters.
Sections du résumé
BACKGROUND
BACKGROUND
Perfusion imaging is one of the methods used to grade glial neoplasms, and in this study we evaluated the role of ASL perfusion in grading brain glioma.
PURPOSE
OBJECTIVE
The aim is to evaluate the role of arterialized cerebral blood volume (aCBV) of multi-delay ASL perfusion for grading glial neoplasm.
MATERIALS AND METHODS
METHODS
This study is a prospective observational study of 56 patients with glial neoplasms of the brain who underwent surgery, and only cases with positive diagnosis of glioma are included to evaluate the novel diagnostic parameter.
RESULTS
RESULTS
In the study, ASL-derived normalized aCBV (naCBV) and T2*DSC-derived normalized CBV (nCBV) are showing very high correlation (Pearson's correlation coefficient value of 0.94) in grading glial neoplasms. naCBV and nCBF are also showing very high correlation (Pearson's correlation coefficient value of 0.876). The study also provides cutoff values for differentiating LGG from HGG for normalized aCBV(naCBV) of ASL, normalized CBV (nCBV), and normalized nCBF derived from T2* DCS as 1.12, 1.254, and 1.31, respectively. ASL-derived aCBV also shows better diagnostic accuracy than ASL-derived CBF.
CONCLUSION
CONCLUSIONS
This study is one of its kind to the best of our knowledge where multi-delay ASL perfusion-derived aCBV is used as a novel imaging biomarker for grading glial neoplasms, and it has shown high statistical correlation with T2* DSC-derived perfusion parameters.
Identifiants
pubmed: 37548164
doi: 10.1177/19714009231193163
pmc: PMC10649543
doi:
Substances chimiques
Spin Labels
0
Biomarkers
0
Contrast Media
0
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
728-735Déclaration de conflit d'intérêts
Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
AJNR Am J Neuroradiol. 2012 Jun;33(6):1081-7
pubmed: 22322605
J Cereb Blood Flow Metab. 2010 Nov;30(11):1821-4
pubmed: 20842161
Neuroradiology. 2010 Apr;52(4):307-17
pubmed: 19841916
PLoS One. 2013 Dec 06;8(12):e81509
pubmed: 24324699
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Magn Reson Imaging. 2010 Jan;28(1):1-7
pubmed: 19695822
Neuroimaging Clin N Am. 2006 May;16(2):259-68, x
pubmed: 16731365
Eur J Radiol. 2014 Oct;83(10):1914-9
pubmed: 25087109
Oncotarget. 2019 Feb 22;10(16):1589-1601
pubmed: 30899427
Proc Natl Acad Sci U S A. 2008 Apr 1;105(13):5213-8
pubmed: 18362333
Semin Roentgenol. 2014 Jan;49(1):39-52
pubmed: 24342674
World Neurosurg. 2016 Apr;88:32-35
pubmed: 26732963
AJNR Am J Neuroradiol. 2003 Nov-Dec;24(10):1989-98
pubmed: 14625221
Neuroimage Clin. 2013 Jul 06;3:1-7
pubmed: 24159561
JAMA Oncol. 2017 Apr 01;3(4):524-548
pubmed: 27918777
Eur J Radiol. 2009 Jun;70(3):465-74
pubmed: 18359598
Magn Reson Med. 2012 May;67(5):1252-65
pubmed: 22084006
Neurology. 2006 Jun 27;66(12):1899-906
pubmed: 16801657
J Clin Invest. 1948 Jul;27(4):476-83
pubmed: 16695568
Radiology. 2003 Aug;228(2):523-32
pubmed: 12819338
J Magn Reson Imaging. 2005 Oct;22(4):475-82
pubmed: 16161080
Magn Reson Med. 2012 Aug;68(2):452-62
pubmed: 22791559
Brain Inj. 2018;32(13-14):1731-1739
pubmed: 30296173
Magn Reson Med. 2015 Jan;73(1):102-16
pubmed: 24715426
Neuro Oncol. 2019 Nov 1;21(Suppl 5):v1-v100
pubmed: 31675094
Radiology. 2008 May;247(2):490-8
pubmed: 18349315
Radiology. 2007 Apr;243(1):148-57
pubmed: 17267695